MRNS May 2024 1.000 call
| Previous Close | 0.4000 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 1.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.0500 - 0.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 865 |
ZacksHere's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks
Marinus Pharmaceuticals (MRNS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Business WireMarinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
RADNOR, Pa., May 17, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in the global Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults.
ZacksAfter Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS)
Marinus Pharmaceuticals (MRNS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
